Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 1, 2013, Pages 81-87

  Körmendy, Dezsö ^a   Hoff, Holger ^a   Hoff, Paula ^a   Bröker, Barbara M ^b   Burmester, Gerd Rüdiger ^a   Brunner Weinzierl, Monika C ^a,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CLINICAL ARTICLE; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL;

ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; CTLA-4 ANTIGEN; CYTOKINES; FLOW CYTOMETRY; HUMANS; MOLECULAR TARGETED THERAPY; REAL-TIME POLYMERASE CHAIN REACTION; SYNOVIAL FLUID;

EID: 84871792706     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37714     Document Type: Article

References (27)

1. Guillemin F, Saraux A, Guggenbuhl P, Roux CH, Fardellone P, Le Bihan E, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis 2005; 64: 1427-30.
2. Pedersen JK, Svendsen AJ, Horslev-Petersen K,. Prevalence of rheumatoid arthritis in the southern part of Denmark. Open Rheumatol J 2011; 5: 91-7.
3. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800.
4. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
5. Chen L,. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-47.
6. Brunner-Weinzierl MC, Hoff H, Burmester GR,. Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases. Arthritis Res Ther 2004; 6: 45-54.
7. Rudd CE,. The reverse stop-signal model for CTLA4 function. Nat Rev Immunol 2008; 8: 153-60.
8. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP,. CTLA-4-mediated inhibition of early events of T cell proliferation. J Immunol 1999; 162: 5813-20.
9. Hoff H, Kolar P, Ambach A, Radbruch A, Brunner-Weinzierl MC,. CTLA-4 (CD152) inhibits T cell function by activating the ubiquitin ligase Itch. Mol Immunol 2010; 47: 1875-81.
10. Maszyna F, Hoff H, Kunkel D, Radbruch A, Brunner-Weinzierl MC,. Diversity of clonal T cell proliferation is mediated by differential expression of CD152 (CTLA-4) on the cell surface of activated individual T lymphocytes. J Immunol 2003; 171: 3459-66.
11. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332: 600-3.
12. Walker LS, Sansom DM,. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852-63.
13. null T cells. J Immunol 2009; 182: 5342-51.
14. Kim YO, Kim HJ, Kim SK, Chung JH, Hong SJ,. Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clin Chem Lab Med 2010; 48: 345-53.
15. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41: 1313-8.
16. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-11.
17. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
18. Castan J, Tenner-Racz K, Racz P, Fleischer B, Broker BM,. Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues. Immunology 1997; 90: 265-71.
19. Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, et al. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice. Arthritis Rheum 2009; 60: 123-32.
20. H17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature 2012; 484: 514-8.
21. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843-50.
22. + T cells in vivo. J Immunol 2011; 186: 5580-9.
23. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG,. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109.
24. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006; 33: 2162-6.
25. Teng GG, Turkiewicz AM, Moreland LW,. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005; 5: 1245-54.
26. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009; 68: 1220-7.
27. Hollander JL, Brown EM Jr, Jessar RA, Brown CY,. Hydrocortisone and cortisone injected into arthritic joints: comparative effects of and use of hydrocortisone as a local antiarthritic agent. J Am Med Assoc 1951; 147: 1629-35.